Literature DB >> 23264882

Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice.

Andrew A Monte1, Vasilis Vasiliou, Kennon J Heard.   

Abstract

As molecular techniques have improved, investigators have attempted to improve pharmaceutical efficacy and safety by making trait associations with genomic, epigenomic, transcriptomic, proteomic, and metabolomic polymorphisms. The 'omics era has seen screening assays for pharmaceutical efficacy and safety translated into clinical practice. This manuscript will discuss each 'omic field and the screening assays available to the clinician. While success has been demonstrated in each 'omic field, many challenges remain. Assays need wider availability, predictive values remain low, and costs remain high. In order for clinicians to realize improved efficacy and safety due 'omic screens, development of improved techniques, combining of 'omic assays, and increased clinical utilization is necessary. This is an exciting time for investigators and clinicians that desire improved pharmaceutical therapy.

Entities:  

Year:  2012        PMID: 23264882      PMCID: PMC3526192          DOI: 10.4172/2153-0645.s5-001

Source DB:  PubMed          Journal:  J Pharmacogenomics Pharmacoproteomics


  110 in total

1.  And now for the proteome...

Authors:  A Abbott
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

2.  Prediction of drug response and safety in clinical practice.

Authors:  Andrew A Monte; Kennon J Heard; Vasilis Vasiliou
Journal:  J Med Toxicol       Date:  2012-03

3.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 4.  Structure of cytochrome p450s and personalized drug.

Authors:  Jing-Fang Wang; Cheng-Cheng Zhang; Kuo-Chen Chou; Dong-Qing Wei
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 5.  The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses.

Authors:  Natalie J Serkova; Theodore J Standiford; Kathleen A Stringer
Journal:  Am J Respir Crit Care Med       Date:  2011-06-16       Impact factor: 21.405

6.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

7.  Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.

Authors:  Ryan Abo; Scott Hebbring; Yuan Ji; Hongjie Zhu; Zhao-Bang Zeng; Anthony Batzler; Gregory D Jenkins; Joanna Biernacka; Karen Snyder; Maureen Drews; Oliver Fiehn; Brooke Fridley; Daniel Schaid; Naoyuki Kamatani; Yusuke Nakamura; Michiaki Kubo; Taisei Mushiroda; Rima Kaddurah-Daouk; David A Mrazek; Richard M Weinshilboum
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

8.  Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver.

Authors:  E E Powell; P A Kroon
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors:  Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

Review 10.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

View more
  5 in total

Review 1.  The State of Data Science in Genomic Nursing.

Authors:  Caitlin Dreisbach; Theresa A Koleck
Journal:  Biol Res Nurs       Date:  2020-04-08       Impact factor: 2.522

Review 2.  Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension.

Authors:  Chayakrit Krittanawong; Andrew S Bomback; Usman Baber; Sripal Bangalore; Franz H Messerli; W H Wilson Tang
Journal:  Curr Hypertens Rep       Date:  2018-07-06       Impact factor: 5.369

3.  Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels.

Authors:  Heiner K Berthold; Nabil G Seidah; Suzanne Benjannet; Ioanna Gouni-Berthold
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

Review 4.  Improved drug therapy: triangulating phenomics with genomics and metabolomics.

Authors:  Andrew A Monte; Chad Brocker; Daniel W Nebert; Frank J Gonzalez; David C Thompson; Vasilis Vasiliou
Journal:  Hum Genomics       Date:  2014-09-01       Impact factor: 4.639

Review 5.  Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease.

Authors:  Theodora Katsila; Evangelia Konstantinou; Ioanna Lavda; Harilaos Malakis; Ioanna Papantoni; Lamprini Skondra; George P Patrinos
Journal:  EBioMedicine       Date:  2016-02-02       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.